Under the new agreement, financial terms of which were not disclosed, the UK contract manufacturing organisation (CMO) will fill and finish a candidate cancer drug for Phase III trials.
SCM completed the first stage of the project earlier this year and, according to Sanofi, the CMO’s ability to meet tight deadlines was key to it winning the new contract.
The Paris firm said it had been: “Very impressed with the manner and speed in which SCM Pharma was able to deliver the project last year,” adding that “Based on its performance, we had no hesitation in approaching and appointing SCM Pharma with another project.”